143 related articles for article (PubMed ID: 32248449)
1. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer.
Kushlinskii NE; Gershtein ES; Alferov AA; Bezhanova SD; Mushtenko VV; Pushkar DY; Matveev VB; Stilidi IS
Bull Exp Biol Med; 2020 Mar; 168(5):673-676. PubMed ID: 32248449
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
4. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
Lein M; Jung K; Laube C; Hübner T; Winkelmann B; Stephan C; Hauptmann S; Rudolph B; Schnorr D; Loening SA
Int J Cancer; 2000 Mar; 85(6):801-4. PubMed ID: 10709099
[TBL] [Abstract][Full Text] [Related]
5. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
6. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors.
Kushlinsky NE; Solovyov YN; Babkina IV; Gershtein ES; Bulicheva IV
Bull Exp Biol Med; 2010 Aug; 149(2):233-5. PubMed ID: 21113498
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms.
Gershtein ES; Levkina NV; Digayeva MA; Laktionov KP; Tereshkina IV; Kushlinsky NE
Bull Exp Biol Med; 2010 Oct; 149(5):628-31. PubMed ID: 21165404
[TBL] [Abstract][Full Text] [Related]
9. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
[TBL] [Abstract][Full Text] [Related]
10. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
11. Matrix Metalloproteinases and Their Tissue Inhibitors in Blood Serum of Patients with Endometrial Cancer: Clinical and Morphological Correlations.
Gershtein ES; Mushtenko SV; Ermilova VD; Levchenko NE; Kushlinskii NE
Bull Exp Biol Med; 2018 May; 165(1):75-79. PubMed ID: 29796809
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of tumor-associated proteases in colorectal cancer.
Kushlinskii NE; Gershtein ES; Korotkova EA; Prorokov VV
Bull Exp Biol Med; 2013 Jan; 154(3):365-9. PubMed ID: 23484202
[TBL] [Abstract][Full Text] [Related]
13. Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients.
Gunes M; Kemik AS; Pirincci N; Gecit I; Taken K; Yuksel MB; Kaba M; Eryilmaz R
Asian Pac J Cancer Prev; 2013; 14(2):873-6. PubMed ID: 23621254
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
15. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.
Fuksiewicz M; Kotowicz B; Rutkowski A; Kowalska M
Tumour Biol; 2015 May; 36(5):3629-35. PubMed ID: 25549795
[TBL] [Abstract][Full Text] [Related]
16. The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower Limb Endovascular Interventions for Peripheral Arterial Disease.
Giagtzidis IT; Kadoglou NP; Mantas G; Spathis A; Papazoglou KO; Karakitsos P; Liapis CD; Karkos CD
Ann Vasc Surg; 2017 Aug; 43():188-196. PubMed ID: 28288884
[TBL] [Abstract][Full Text] [Related]
17. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
[TBL] [Abstract][Full Text] [Related]
18. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract][Full Text] [Related]
19. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
20. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
